Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of AZD9977 in Healthy Males
NCT02532998Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of balcinrenone in heart failure (HF) and chronic kidney disease (CKD) (8 arms), sponsored by AstraZeneca. Primary endpoint: Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine. Started Sep 2015; status: completed.
02
Drugs
balcinrenone
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02532998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532998.